INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 21.41 billion | 11% | North America |
| By Technology | By Technique | By Application |
|---|---|---|
|
|
|
SCOPE OF THE REPORT
Cancer/Tumour Profiling Market Overview
Cancer/tumour profiling market size was valued at USD 8.37 billion in 2020 and is projected to reach USD 21.41 billion by 2029, growing at a CAGR of 11% from 2022 to 2029.
Cancer/tumour profiling is a type of testing that searches for specific DNA changes in a patient’s tumour, and it has seen major breakthroughs in recent years. Tumor profiling is a technique used by oncologists to see if a patient’s tumour’s pathways line up with existing targeted treatments. Obtaining a sample of tumour tissue is the first step in tumour profiling. A core biopsy is commonly used to obtain the tissue; however, it can also be obtained during surgery. Tumor DNA is taken from tumour cells, purified, and delivered to a lab when the tissue sample is acquired. The DNA is examined, or sequenced, for gene alterations that may cause the tumour to respond to specific treatments.
Cancer/tumour profiling gives information on the genes that cause cancer, which can help researchers better understand how cancer works. Cancer profiling is not only effective in the molecular profiling of common malignancies like lymphoma and breast cancer, but also in the molecular profiling of lung cancer, prostate cancer, and acute leukaemia. Cancer profiling has become increasingly important in molecular diagnosis, since a better understanding of cancer tumours allows clinicians to make more informed therapeutic decisions and prevent “over-treating” cancer patients.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2029 |
| Base year | 2021 |
| Estimated year | 2022 |
| Forecasted year | 2022-2029 |
| Historical period | 2018-2020 |
| Unit | Value (USD Billion) |
| Segmentation | By Technology, By Technique, By Application, Region
|
| By Technology |
|
| By Technique |
|
| By Application |
|
| By Region |
|
Furthermore, the expansion of the cancer/tumor profiling market is being fuelled by an increase in cancer research and financing initiatives, as well as technological advancements in profiling technologies. Moreover, throughout the projected period, the growing demand for personalised medication and point-of-care diagnostics is expected to provide substantial growth possibilities for market participants. However, the substantial capital investment required for biomarker discovery, as well as technological challenges with sample collection and storage, are limiting market expansion to some extent.
In cancer cells, each malignancy has its own set of molecular alterations. Technological advancements have made molecular profile analysis possible, allowing clinicians to discriminate between cancer cells and healthy cells based on molecular distinctions. The application of multiple technologies to investigate the underlying traits observed in cancer cells is known as molecular profiling. Biomarkers are substances found in the body that display either normal or abnormal symptoms or processes; aberrant signs may suggest disease. Cancer/tumor profiling provides details on the genes that cause cancer. Cancer profiling is not only beneficial in the molecular profiling of common diseases like breast and lymphoma cancer, but also in the molecular profiling of prostate cancer, lung cancer, and acute leukaemia. Cancer/tumor profiling is important in molecular diagnostics because a better understanding of cancer tumours aids physicians in making appropriate therapeutic decisions and avoiding “over-treatment” of cancer patients.
Furthermore, the market is being propelled forward by growing investments by pharmaceutical and biotechnology businesses in research and development (R&D) operations for the launch of novel medicines and new drug design approaches. Other factors, including as an increase in clinical trials, increased adoption of immunoassay techniques, advantageous reimbursement policies, improved healthcare infrastructure, and technical breakthroughs, are all contributing to the market’s optimistic outlook.
One of the most immediate concerns facing service providers is sample collection, which is followed by sample access. These samples must be subjected to stringent quality control, and they must be maintained in the proper conditions to avoid loss. Technological breakthroughs have aided the development and application of tumour profiling technologies, which can identify crucial characteristics of a patient’s disease at an early stage and hence influence the therapy selection for that patient. Evidence of the biomarker’s clinical validity and utility is required for biomarker-based testing to be accepted in clinical applications. This is critical not just for assisting clinicians in their decision-making, but also for obtaining regulatory clearances and test reimbursements. However, gathering the data needed to demonstrate clinical validity and utility can be a time-consuming and costly procedure, made much more difficult by the lack of standardised norms. All these factors may act as market restraints.
Cancer/Tumour Profiling Market Segment Analysis
The global cancer/tumor profiling market is segmented on the basis of technology, technique, application, and region. Based on technology, the market is segmented into sequencing technique, next-generation sequencing (NGS), in situ hybridization, immunohistochemistry, and others. The market for fluorescence in-situ hybridization (FISH) is very large and holds a major share. When compared to traditional methods, FISH profiling takes less time. It makes chromosomal microdeletion, amplification, and translocation much easier. In addition, a novel alternative method known as next-generation sequencing (NGS) allows clinicians to screen several cancer genes at the same time. Material from a patient’s tumour that has been biopsied or surgically excised can be used for next-generation sequencing.
Based on technique, the market is segmented into genomics, metabolomics, proteomics, and epigenetics. The genomics market has a large share of the market. Genomics has various advantages, including lower costs, faster screening times, and assistance in finding large-sized genomes. The study of genes, known as genomics, is making it possible to anticipate, diagnose, and treat diseases with greater precision and personalization than ever before. The human genome is made up of three billion base pairs of DNAs that are individually organised to give us our basic anatomy and individual features like height and hair colour. In addition, metabolomics is a good way to find biomarkers and metabolic changes in cancer patients.
The research applications category accounts for the majority of the market. Biomarkers are becoming increasingly important in the development of treatment regimens for cancer patients, thanks to rapid advancements in customised targeted therapy and gene profiling methods. Genome-based prognostic biomarkers are now being used in the early stages of clinical trials to predict the prognosis of a variety of cancers, as well as to aid in therapy and medication development.
Cancer/Tumour Profiling Market Players
Key players operating the global cancer/tumour profiling market includes Qiagen N.V., Illumina Inc., Neogenomics Inc., HTG Molecular Diagnostics, Inc., Genomic Health, Helomics Corporation, Caris Life Sciences, Nanostring Technologies, Oxford Gene Technology, Ribomed Biotechnologies Inc.
- QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries.
- Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function.
- NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer.
Who Should Buy? Or Key Stakeholders
- Healthcare Industry
- Hospitals and Clinics
- Clinical Laboratories
- Pharmaceutical Industry
- Scientific Research and Development
- Investors
- Manufacturing companies
- End user companies
- Others
Cancer/Tumour Profiling Market Regional Analysis
The global breath analyser market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
- Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
- South America: includes Brazil, Argentina and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
During the projected period, the North American region is expected to have the greatest CAGR. This is mostly attributable to rising disposable income and increased urbanisation in these countries. The presence of significant companies, technological advancements, rising cancer occurrence, and increased expenditure in oncology research to identify novel treatments are all aspects that contribute to this segment’s large share. The Asia-Pacific area, on the other hand, is predicted to develop at the fastest rate during the forecast period. The vast population size, advances in medical knowledge, and increased disposable income all contribute to this growth.
Key Market Segments: Cancer/tumour profiling Market
Cancer/Tumour Profiling Market by Technology, 2020-2029, (USD Million)
- Sequencing Technique
- Next-Generation Sequencing (NGS)
- In Situ Hybridization
- Immunohistochemistry
Cancer/Tumour Profiling Market by Technique, 2020-2029, (USD Million)
- Genomics
- Metabolomics
- Proteomics
- Epigenetic
Cancer/Tumour Profiling Market by Application, 2020-2029, (USD Million)
- Personalized Cancer Medicine
- Oncological Diagnostics
- Research Applications
Cancer/Tumour Profiling Market by Region, 2020-2029, (USD Million)
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Important Countries in All Regions Are Covered.
Table of Content
- Introduction
- Market Definition
- Market Segmentation
- Research Timelines
- Assumptions and Limitations
- Research Methodology
- Data Mining
- Secondary Research
- Primary Research
- Subject-Matter Experts’ Advice
- Quality Checks
- Final Review
- Data Triangulation
- Bottom-Up Approach
- Top-Down Approach
- Research Flow
- Data Sources
- Data Mining
- Executive Summary
- Market Overview
- Global Cancer/Tumour Profiling Market Outlook
- Market Drivers
- Market Restraints
- Market Opportunities
- Impact of Covid-19 On Global Cancer/Tumour Profiling Market
- Global Cancer/Tumour Profiling Market Outlook
- Global Cancer/Tumour Profiling Market by Technology, (USD Million)
- Sequencing Technique
- Next-Generation Sequencing (NGS)
- In Situ Hybridization
- Immunohistochemistry
- Global Cancer/Tumour Profiling Market by Technique, (USD Million)
- Genomics
- Metabolomics
- Proteomics
- Epigenetic
- Global Cancer/Tumour Profiling Market by Application, (USD Million)
- Personalized Cancer Medicine
- Oncological Diagnostics
- Research Applications
- Global Cancer/Tumour Profiling Market by Region, (USD Million)
- Introduction
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- South-East Asia
- Rest of Asia-Pacific
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Russia
- Rest of Europe
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
- Company Profiles* (Business Overview, Company Snapshot, Techniques Offered, Recent Developments)
-
-
- Qiagen N.V.
- Illumina Inc.
- Neogenomics Inc.
- HTG Molecular Diagnostics, Inc.
- Genomic Health
- Helomics Corporation
- Caris Life Sciences
- Nanostring Technologies
- Oxford Gene Technology
- Ribomed Biotechnologies Inc
- Others *The Company List Is Indicative
-
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 2Â Â Â Â Â Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 3Â Â Â Â Â Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 4Â Â Â Â Â Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKET BY REGION (USD MILLIONS) 2020-2029
TABLE 5Â Â Â Â Â Â Â Â Â US CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 6Â Â Â Â Â Â Â Â Â US CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 7Â Â Â Â Â Â Â Â Â US CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 8Â Â Â Â Â Â Â Â Â CANADA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 9Â Â Â Â Â Â Â Â Â CANADA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 10Â Â Â Â Â Â CANADA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 11Â Â Â Â Â Â MEXICO CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 12Â Â Â Â Â Â MEXICO CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 13Â Â Â Â Â Â MEXICO CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 14Â Â Â Â Â Â BRAZIL CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 15Â Â Â Â Â Â BRAZIL CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 16Â Â Â Â Â Â BRAZIL CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 17Â Â Â Â Â Â ARGENTINA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 18Â Â Â Â Â Â ARGENTINA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 19Â Â Â Â Â Â ARGENTINA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 20Â Â Â Â Â Â COLOMBIA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 21Â Â Â Â Â Â COLOMBIA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 22Â Â Â Â Â Â COLOMBIA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 23Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 24Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 25Â Â Â Â Â Â REST OF SOUTH AMERICA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 26Â Â Â Â Â Â INDIA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 27Â Â Â Â Â Â INDIA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 28Â Â Â Â Â Â INDIA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 29Â Â Â Â Â Â CHINA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 30Â Â Â Â Â Â CHINA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 31Â Â Â Â Â Â CHINA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 32Â Â Â Â Â Â JAPAN CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 33Â Â Â Â Â Â JAPAN CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 34Â Â Â Â Â Â JAPAN CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 35Â Â Â Â Â Â SOUTH KOREA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 36Â Â Â Â Â Â SOUTH KOREA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 37Â Â Â Â Â Â SOUTH KOREA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 38Â Â Â Â Â Â AUSTRALIA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 39Â Â Â Â Â Â AUSTRALIA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 40Â Â Â Â Â Â AUSTRALIA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 41Â Â Â Â Â Â SOUTH-EAST ASIA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 42Â Â Â Â Â Â SOUTH-EAST ASIA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 43Â Â Â Â Â Â SOUTH-EAST ASIA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 44Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 45Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 46Â Â Â Â Â Â REST OF ASIA PACIFIC CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 47Â Â Â Â Â Â GERMANY CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 48Â Â Â Â Â Â GERMANY CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 49Â Â Â Â Â Â GERMANY CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 50Â Â Â Â Â Â UK CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 51Â Â Â Â Â Â UK CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 52Â Â Â Â Â Â UK CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 53Â Â Â Â Â Â FRANCE CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 54Â Â Â Â Â Â FRANCE CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 55Â Â Â Â Â Â FRANCE CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 56Â Â Â Â Â Â ITALY CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 57Â Â Â Â Â Â ITALY CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 58Â Â Â Â Â Â ITALY CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 59Â Â Â Â Â Â SPAIN CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 60Â Â Â Â Â Â SPAIN CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 61Â Â Â Â Â Â SPAIN CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 62Â Â Â Â Â Â RUSSIA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 63Â Â Â Â Â Â RUSSIA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 64Â Â Â Â Â Â RUSSIA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 65Â Â Â Â Â Â REST OF EUROPE CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 66Â Â Â Â Â Â REST OF EUROPE CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 67Â Â Â Â Â Â REST OF EUROPE CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 68Â Â Â Â Â Â UAE CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 69Â Â Â Â Â Â UAE CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 70Â Â Â Â Â Â UAE CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 71Â Â Â Â Â Â SAUDI ARABIA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 72Â Â Â Â Â Â SAUDI ARABIA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 73Â Â Â Â Â Â SAUDI ARABIA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 74Â Â Â Â Â Â SOUTH AFRICA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 75Â Â Â Â Â Â SOUTH AFRICA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 76Â Â Â Â Â Â SOUTH AFRICA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
TABLE 77Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER/TUMOUR PROFILING MARKET BY TECHNOLOGY (USD MILLIONS) 2020-2029
TABLE 78Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER/TUMOUR PROFILING MARKET BY TECHNIQUE (USD MILLIONS) 2020-2029
TABLE 79Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA CANCER/TUMOUR PROFILING MARKET BY APPLICATION (USD MILLIONS) 2020-2029
LIST OF FIGURES
FIGURE 1Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY TECHNOLOGY, USD MILLION, 2020-2029
FIGURE 10Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY TECHNIQUE, USD MILLION, 2020-2029
FIGURE 11Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY APPLICATION, USD MILLION, 2020-2029
FIGURE 12Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY REGION, USD MILLION, 2020-2029
FIGURE 13    PORTER’S FIVE FORCES MODEL
FIGURE 14Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY TECHNOLOGY, 2020
FIGURE 15Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY TECHNIQUE 2020
FIGURE 16Â Â Â Â GLOBAL CANCER/TUMOUR PROFILING MARKETBY APPLICATION 2020
FIGURE 17Â Â Â Â CANCER/TUMOUR PROFILING MARKETBY REGION 2020
FIGURE 18Â Â Â Â MARKET SHARE ANALYSIS
FIGURE 19Â Â Â Â QIAGEN N.V.: COMPANY SNAPSHOT
FIGURE 20Â Â Â Â ILLUMINA INC.: COMPANY SNAPSHOT
FIGURE 21Â Â Â Â NEOGENOMICS INC.: COMPANY SNAPSHOT
FIGURE 22Â Â Â Â HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT
FIGURE 23Â Â Â Â GENOMIC HEALTH: COMPANY SNAPSHOT
FIGURE 24Â Â Â Â HELOMICS CORPORATION: COMPANY SNAPSHOT
FIGURE 25Â Â Â Â CARIS LIFE SCIENCES: COMPANY SNAPSHOT
FIGURE 26Â Â Â Â NANOSTRING TECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 27Â Â Â Â OXFORD GENE TECHNOLOGY: COMPANY SNAPSHOT
FIGURE 28Â Â Â Â RIBOMED BIOTECHNOLOGIES INC: COMPANY SNAPSHOT
FAQ
Cancer/tumour profiling market size was valued at USD 8.37 billion in 2020 and is projected to reach USD 21.41 billion by 2029, growing at a CAGR of 11% from 2022 to 2029 due to the increase in cancer research and financing initiatives.
North America held more than 43% of the cancer/tumour profiling market revenue share in 2021 and will witness growth with the surging demand mostly attributable to rising disposable income and increased urbanization in these countries.
Growing investments by pharmaceutical and biotechnology businesses in research and development (R&D) operations for the launch of novel medicines and new drug design approaches will drive the market in the future.
The global cancer/tumour profiling market registered a CAGR of 11% from 2022 to 2029.
Biomarkers are becoming increasingly important in the development of treatment regimens for cancer patients and also leading application.
North America is the largest market for cancer/tumour profiling market.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.